Novel target for treating Alzheimer's Diseases: Crosstalk between the Nrf2 pathway and autophagy

Weiwei Zhang1, Cong Feng1, Hong Jiang1

  • 1Department of Health Laboratory Technology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning 110122, People's Republic of China.

Ageing Research Reviews
|November 4, 2020
PubMed

Insights

The Keap1-Nrf2-ARE pathway and autophagy, linked by p62, protect cells from oxidative damage. Maintaining this p62-Keap1-Nrf2 feedback loop may treat neurodegenerative diseases like Alzheimer's.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Neuroscience

Background:

  • The Keap1-Nrf2-ARE pathway and autophagy are critical cellular defense systems against oxidative stress and for maintaining homeostasis.
  • p62/SQSTM1 acts as a crucial link between the Nrf2 pathway and autophagy, mediating the interaction between Keap1 and Nrf2.
  • Dysregulation of this pathway is implicated in neurodegenerative diseases, including Alzheimer's disease (AD).

Purpose of the Study:

  • To elucidate the role of the p62-Keap1-Nrf2 positive feedback loop in cellular defense mechanisms.
  • To investigate the involvement of the Nrf2 pathway and autophagy in the context of neurodegenerative diseases.
  • To explore the therapeutic potential of targeting the p62-Keap1-Nrf2 pathway for AD treatment.

Main Methods:

  • Investigated the molecular interactions between p62, Keap1, and Nrf2.
  • Examined the role of p62 phosphorylation in regulating Keap1-Nrf2 binding and subsequent Nrf2 activation.
  • Studied the involvement of selective autophagy (LC3 recruitment) in Keap1 degradation.
  • Analyzed the positive feedback loop created by Nrf2-mediated upregulation of p62.
  • Correlated p62-activated Nrf2 pathway activity with markers of neurodegeneration.

Main Results:

  • Phosphorylation of p62 enhances its affinity for Keap1, leading to Nrf2 release and subsequent nuclear translocation.
  • The p62-Keap1 heterodimer recruits LC3, facilitating Keap1 degradation via selective autophagy.
  • A positive feedback loop is established where Nrf2 upregulates p62 expression, amplifying cellular protection.
  • The p62-activated Nrf2 pathway is identified as a significant marker in neurodegenerative diseases.
  • This pathway is involved in clearing reactive oxygen species (ROS) and protein aggregates in AD.

Conclusions:

  • The p62-Keap1-Nrf2 positive feedback loop is a vital bridge between the Nrf2 pathway and autophagy, crucial for cellular defense.
  • This pathway plays a significant role in mitigating oxidative damage and protein aggregation characteristic of AD.
  • Maintaining the homeostasis of the p62-Keap1-Nrf2 pathway presents a promising therapeutic target for Alzheimer's disease and other neurodegenerative conditions.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
617
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.5K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.1K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
83.8K